Compare CDMOs with metabolic disease manufacturing expertise for GLP-1 agonists, insulin analogs, and oral antidiabetics. Filter by peptide capabilities, dosage form, and scale.
101 companies listed
The metabolic disease space is experiencing unprecedented demand growth, driven by GLP-1 receptor agonists (semaglutide, tirzepatide) for diabetes and obesity. Global GLP-1 manufacturing capacity is severely constrained, with demand outstripping supply by an estimated 2-3x. CDMOs with peptide synthesis, fermentation-based peptide production, and prefilled pen/syringe fill-finish capabilities are the most sought-after partners in pharma.
Peptide manufacturing is the bottleneck. GLP-1 agonists are peptides produced either by solid-phase peptide synthesis (SPPS) or recombinant DNA technology. SPPS is suitable for shorter peptides but faces scale limitations. Recombinant production in E. coli or yeast (Pichia pastoris) enables larger scale but requires fermentation expertise, refolding optimization, and complex purification. CDMOs that can offer both approaches provide sponsors with optionality.
Device integration drives complexity. Most metabolic disease injectables are delivered via pen injectors or autoinjectors for patient self-administration. CDMOs need cartridge filling capability (3mL cartridges for pens), device assembly experience, and combination product regulatory knowledge. The fill-finish step for cartridges requires different equipment and expertise than standard vial filling.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.